These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 31140155)
21. Dual-phase Kuo HC; Hsiao IT; Hsieh CJ; Huang CY; Huang KL; Wai YY; Chuang WL; Kung MP; Chu YC; Yen TC; Lin KJ; Huang CC J Formos Med Assoc; 2017 Dec; 116(12):964-972. PubMed ID: 28434708 [TBL] [Abstract][Full Text] [Related]
22. GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain. Yao CH; Lin KJ; Weng CC; Hsiao IT; Ting YS; Yen TC; Jan TR; Skovronsky D; Kung MP; Wey SP Appl Radiat Isot; 2010 Dec; 68(12):2293-7. PubMed ID: 20638295 [TBL] [Abstract][Full Text] [Related]
23. Quantification of 18F-florbetapir PET: comparison of two analysis methods. Hutton C; Declerck J; Mintun MA; Pontecorvo MJ; Devous MD; Joshi AD; Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):725-32. PubMed ID: 25652817 [TBL] [Abstract][Full Text] [Related]
24. Sex Moderates the Impact of Diagnosis and Amyloid PET Positivity on Hippocampal Subfield Volume. Caldwell JZK; Berg JL; Shan G; Cummings JL; Banks SJ; J Alzheimers Dis; 2018; 64(1):79-89. PubMed ID: 29865063 [TBL] [Abstract][Full Text] [Related]
25. Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease. Toledo JB; Bjerke M; Da X; Landau SM; Foster NL; Jagust W; Jack C; Weiner M; Davatzikos C; Shaw LM; Trojanowski JQ; JAMA Neurol; 2015 May; 72(5):571-81. PubMed ID: 25822737 [TBL] [Abstract][Full Text] [Related]
26. Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval. Cortes-Blanco A; Prieto-Yerro C; Martinez-Lazaro R; Zamora J; Jiménez-Huete A; Haberkamp M; Pohly J; Enzmann H; Zinserling J; Strassmann V; Broich K Alzheimers Dement; 2014 Oct; 10(5 Suppl):S395-9. PubMed ID: 24418060 [TBL] [Abstract][Full Text] [Related]
27. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. Landau SM; Fero A; Baker SL; Koeppe R; Mintun M; Chen K; Reiman EM; Jagust WJ J Nucl Med; 2015 Apr; 56(4):567-74. PubMed ID: 25745095 [TBL] [Abstract][Full Text] [Related]
28. Progress of Brain Amyloid Deposition in Familial Alzheimer's Disease with Taiwan D678H APP Mutation. Weng YC; Hsiao IT; Huang CY; Huang KL; Liu CH; Chang TY; Yen TC; Lin KJ; Huang CC J Alzheimers Dis; 2018; 66(2):775-787. PubMed ID: 30320594 [TBL] [Abstract][Full Text] [Related]
29. Chemistry. Expanding the scope of fluorine tags for PET imaging. Zhu L; Ploessl K; Kung HF Science; 2013 Oct; 342(6157):429-30. PubMed ID: 24159034 [No Abstract] [Full Text] [Related]
30. FDA approves 18F-florbetapir PET agent. J Nucl Med; 2012 Jun; 53(6):15N. PubMed ID: 22661593 [No Abstract] [Full Text] [Related]
31. Amyloid PET/MRI in the differential diagnosis of dementia. Vercher-Conejero JL; Rubbert C; Kohan AA; Partovi S; O'Donnell JK Clin Nucl Med; 2014 Jun; 39(6):e336-9. PubMed ID: 23856830 [TBL] [Abstract][Full Text] [Related]
32. Reduced acquisition time PET pharmacokinetic modelling using simultaneous ASL-MRI: proof of concept. Scott CJ; Jiao J; Melbourne A; Burgos N; Cash DM; De Vita E; Markiewicz PJ; O'Connor A; Thomas DL; Weston PS; Schott JM; Hutton BF; Ourselin S J Cereb Blood Flow Metab; 2019 Dec; 39(12):2419-2432. PubMed ID: 30182792 [TBL] [Abstract][Full Text] [Related]
33. [Safety and Effectiveness of NEPTIS Plug-01 and Florbetapir ( Nakamura T; Matsumura T; Yamamoto Y; Senda M Kaku Igaku; 2019; 56(1):127-134. PubMed ID: 31554771 [TBL] [Abstract][Full Text] [Related]
34. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals. Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW; Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939 [TBL] [Abstract][Full Text] [Related]
35. Is in vivo amyloid distribution asymmetric in primary progressive aphasia? Martersteck A; Murphy C; Rademaker A; Wieneke C; Weintraub S; Chen K; Mesulam MM; Rogalski E; Ann Neurol; 2016 Mar; 79(3):496-501. PubMed ID: 26600088 [TBL] [Abstract][Full Text] [Related]
36. Amyloid-β positron emission tomography in the diagnostic evaluation of alzheimer disease: summary of primary findings and conclusions. Pearson SD; Ollendorf DA; Colby JA JAMA Intern Med; 2014 Jan; 174(1):133-4. PubMed ID: 24081022 [No Abstract] [Full Text] [Related]
37. Current status of PET-imaging probes of β-amyloid plaques. Koo J; Byun Y Arch Pharm Res; 2013 Oct; 36(10):1178-84. PubMed ID: 23812777 [TBL] [Abstract][Full Text] [Related]
38. Brain amyloid imaging--FDA approval of florbetapir F18 injection. Yang L; Rieves D; Ganley C N Engl J Med; 2012 Sep; 367(10):885-7. PubMed ID: 22931256 [No Abstract] [Full Text] [Related]
39. Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Fleisher AS; Chen K; Liu X; Ayutyanont N; Roontiva A; Thiyyagura P; Protas H; Joshi AD; Sabbagh M; Sadowsky CH; Sperling RA; Clark CM; Mintun MA; Pontecorvo MJ; Coleman RE; Doraiswamy PM; Johnson KA; Carpenter AP; Skovronsky DM; Reiman EM Neurobiol Aging; 2013 Jan; 34(1):1-12. PubMed ID: 22633529 [TBL] [Abstract][Full Text] [Related]
40. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease. Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW; J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]